2020
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?
Bewersdorf JP, Zeidan AM. Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? Best Practice & Research Clinical Haematology 2020, 33: 101222. PMID: 33279182, DOI: 10.1016/j.beha.2020.101222.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaRandomized clinical trialsMyelodysplastic syndromeClinical trialsCheckpoint inhibitorsMyeloid leukemiaRecent randomized clinical trialsRecent clinical trial dataEarly phase clinical trialsImmune checkpoint inhibitorsMultiple novel agentsClinical trial dataPhase clinical trialsClinical trial designSynergistic combination therapyImmunophenotypic biomarkersRandomized trialsCombination therapySolid malignanciesNovel agentsTrial designTrial dataNovel targetAvailable evidenceTrialsFedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis.
Schiffer M, Kowalski A, Zhao J, Bewersdorf JP, Lewis RS, Zeidan AM. Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis. Drugs Of Today 2020, 56: 755-768. PMID: 33332482, DOI: 10.1358/dot.2020.56.12.3230206.Peer-Reviewed Original ResearchConceptsSecondary myelofibrosisClinical holdSelective Janus kinase 2 inhibitorNovel oral agentsCommon adverse effectsClinical trial dataFurther drug developmentGastrointestinal symptomsLiver transaminasesOral agentsSymptom burdenJanus kinase 2 inhibitorDrug AdministrationMyeloproliferative neoplasmsTrial dataU.S. FoodAdverse effectsKinase 2 inhibitorPhase IIDrug developmentMyelofibrosisSignificant reductionFurther investigationFedratinibSplenomegaly
2019
Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Bewersdorf JP, Stahl M, Zeidan AM. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia? Leukemia & Lymphoma 2019, 60: 1354-1369. PMID: 30652518, DOI: 10.1080/10428194.2018.1546854.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAML patientsPivotal clinical trial dataOverall survival rateAcute myeloid leukemiaClinical trial dataMechanism of actionIntensive chemotherapyRefractory AMLOlder patientsAML treatmentCD33 antibodyPreclinical dataMyeloid leukemiaClinical developmentTherapeutic revolutionUS FoodDrug AdministrationSurvival rateAdvanced stagePatientsFDA approvalTrial dataPromising agentNovel therapeuticsNew drugs